So finer points of Amgen...

So outside of why are not filthy rish and retired yet or broke trading discussions....a few finer points I don't think have been really discussed.

" These terms and conditions are non-binding and, accordingly, the closing of a Potential Transaction with the Counterparty is subject to, among other things, satisfactory completion of diligence by and negotiations with the Counterparty, the execution of definitive documents, and other conditions necessary to complete the transaction, including any required regulatory approvals"

LOL, all the ifs and buts seem std issue but the fact that UNS released it, Amgen are happy to have released it then if the deal doesn't get done then UNS folk should be shot. Compromises will need to be made and expect them to be made....but the specific mention of regulatory approvals?  

Would I be right in assuming this is financial/business regulatory requirements and NOT pharma regulatory approvals?


Scondly...
"In addition to the Agreement, we have a pre-existing Master Feasibility and Customization Agreement with the Counterparty entered into in the ordinary course of our business on December 2, 2015"

How is it that as an ASX listed company UNS did not release a vanilla statement on the ASX stating a multi-national pharma had signed a Feasability and Customisation agreement?  It surely is associated with some sort of revenue which given the quarterly losses make it material. Its going to utilise the finite resources and include the need for further customisation/R&D which the company said was winding down. I just don't get how UNS can just roll along keeping such onfo to themselves and not releasing it on the ASX????